Doximity Inc. (NYSE:DOCS) is one of the oversold stocks to buy now. On December 15, Morgan Stanley upgraded Doximity to Overweight from Equal Weight with a price target of $65, which was increased from $62. Morgan Stanley stated that Doximity’s recent stock underperformance is inconsistent with the company’s business checks and the platform’s growing user engagement. The firm suggested that both company guidance and Street estimates appear conservative, creating what they view as an attractive entry point ...

Core Insights - Doximity, Inc. reported adjusted earnings per share (EPS) of 45 cents for Q2 fiscal 2026, a 50% increase year over year, exceeding the Zacks Consensus Estimate by 18.4% [1][8] - The company's revenues reached $168.5 million in Q2, reflecting a year-over-year growth of 23.2% and surpassing the Zacks Consensus Estimate by 6.8% [2][8] Revenue Breakdown - Subscription revenues amounted to $159.5 million, up 23% year over year, driven by increased spending from existing customers and a net revenue retention rate of 118% [3] - Other revenues totaled $9.1 million, marking a 25.9% increase year over year [3] Margin Analysis - Gross profit increased by 23.5% year over year to $152.1 million, with a gross margin expansion of 30 basis points to 90.3% [4][8] - Operating profit was $63.7 million, a 19.8% increase from the prior year, although the operating margin contracted by 100 basis points to 37.8% [5][8] Financial Position - Doximity ended Q2 fiscal 2026 with cash and cash equivalents of $169.2 million, up from $137.3 million at the end of Q1 [6] - Cumulative net cash from operating activities was $156 million, compared to $109.6 million a year ago [6] Future Guidance - For Q3 fiscal 2026, Doximity expects revenues between $180 million and $181 million, exceeding the Zacks Consensus Estimate of $178.2 million [7] - The full fiscal year revenue outlook has been raised to between $640 million and $646 million, up from the previous estimate of $628 million to $636 million [9] Product and Engagement Highlights - The company introduced multiple product updates focused on AI and workflow expansion, including the integration of Pathway's medical dataset into DoxGPT [11] - Record engagement was noted with over 650,000 unique prescribers utilizing various digital tools, and AI-optimized program adoption accounted for 40% of bookings [12]

Core Insights - Experity has launched AI Scribe, an AI-driven tool designed to enhance documentation efficiency in urgent care settings by capturing patient visits in real time and generating structured documentation within electronic medical records [1][2]. Company Overview - Experity, supported by private-equity firm GTCR, has deployed its AI Scribe tool across 5,700 urgent care clinics in the U.S. as of October 13 [2]. - Nearly half of all urgent care centers in the U.S. utilize Experity's software platform, indicating a significant market presence [5]. Technology and Functionality - AI Scribe employs ambient listening technology to recognize spoken details during patient visits, interpret complex symptoms, and highlight relevant health indicators, streamlining the documentation process [2][4]. - Clinicians can access AI Scribe on tablets or smartphones without the need for additional application installations, enhancing usability [3]. Industry Challenges - Urgent care providers face challenges in balancing efficiency and patient experience due to documentation overload, which can lead to clinician burnout and workflow inefficiencies [4]. - The urgent care model relies on speed and patient flow, making effective communication with patients crucial for positive outcomes [4]. Impact on Patient Care - The introduction of AI Scribe allows urgent care providers to focus more on patient interaction while documentation occurs quickly and accurately in the background, potentially improving patient satisfaction [4][6].